History of AIDS Research Funding: First Federal Allocation in 1983
Federal funding for AIDS research in the United States began in 1983, when Congress appropriated $19 million through the Supplemental Appropriations Act (P.L. 98-43). This marked the first dedicated federal investment in what would become a massive, sustained research enterprise.
Context
- 1981: First MMWR reports of Pneumocystis pneumonia in young gay men (Los Angeles) and Kaposi's sarcoma (New York).
- 1982: CDC coins term "AIDS"; cases rising exponentially.
- 1983: May — Isolation of LAV (later HIV) by Montagnier's group at Pasteur Institute. July — $19M supplemental appropriation for NIH/CDC. September — CDC identifies major transmission routes.
- 1984: Gallo group confirms HTLV-III/LAV as causative agent; blood test developed.
- 1985: First HIV antibody test licensed; blood supply screening begins.
Funding Trajectory
- 1983: $19M (supplemental)
- 1985: ~$200M
- 1990: >$1B
- 2023: ~$3.5B (NIH) + global PEPFAR/Global Fund
The 1983 appropriation—though modest by later standards—was the critical seed that enabled virology, epidemiology, and early therapeutic research (e.g., AZT development) to accelerate.
HIV & AIDS - Related Articles
- AIDS vs. Autoimmune Hepatitis: Key Differences in Cause, Transmission, and Treatment
- HIV and Infection Risk: Understanding Immune System Vulnerability
- STD and HIV Transmission: How They Spread and How to Prevent It
- Understanding HIV Transmission: Top Causes of Infection
- HIV Transmission Facts: Why Casual Contact Poses No Risk
- Understanding HIV & AIDS: Life Expectancy with Modern Treatment
- Understanding the Metabolic Syndrome Link in HIV Lipodystrophy
